Hemophilia Gene Therapy: First, Do No Harm
Speaker: Dr. Len Valentino
NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the latest in research,…
Pfizer has announced positive results from their global phase 3 BASIS clinical study of marstacimab, the company’s investigational, subcutaneous therapy that targets an anticoagulant protein known as tissue factor pathway inhibitor (TFPI).…